南昌市第八人民医院如何资料.pptVIP

下载本文档

3
0
约 45页
2016-06-27 发布于湖北
举报
版权申诉

南昌市第八人民医院如何资料.ppt

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

丙肝的预防经皮和黏膜途径传播的预防推行安全注射。对牙科器械、内镜等医疗器具应严格消毒。医务人员接触患者血液及体液时应戴手套。对静脉吸毒者进行心理咨询和安全教育,劝其戒毒。不共用剃须刀及牙具等,理发用具、穿刺和文身等用具应严格消毒。丙肝的预防筛选HCV现症感染者筛选献血员有输血制品病史长期血液透析纹身转氨酶升高者治愈现症感染者是预防HCV传播的最有效方法规范检测、诊断是迈向治愈丙肝的关键第一步筛查咨询检测评估治愈治疗慢性丙肝是可以治愈的疾病!! 提高丙肝早期诊断率已经成为全球共识第三届 2006年丹麦哥本哈根主题: Get Tested 第四届 2007年比利时布鲁塞尔主题: Hepatitis? Get Tested! 呼吁各相关部门、学会和协会帮助高危人群获得及时检测 * Over the past 2 decades, there has been substantial improvement in treatment outcomes for chronic HCV-1 infection. Interferons (IFN) are produced by the innate immune response against viral infections, and when first used as monotherapy in the late 1980s and early 1990s to treat HCV-1, SVR rates were around 7–11%. This poor response is due to the relatively short half-life of the protein following subcutaneous injections (~8 hours). RBV is a nucleoside analog that has antiviral efficacy and appears to work synergistically with IFN, resulting in SVR rates of up to 37% when given in combination with IFN.1 To resolve the problem of the short half-life of conventional IFNs, an inert molecule of polyethylene glycol (PEG) was covalently bonded to the IFN protein to increase its molecular weight.1 This delays its absorption and degradation and thus prolongs its serum half-life. Two pegylated IFNs, pegIFN α-2a (Pegasys?, Hoffmann-La Roche Inc) and pegIFN α-2b (PegIntron?, Merck) are currently licensed and, in combination with RBV, formed the standard of care against HCV-1 until recently, and result in SVR rates of around 40% in these patients. Bocepravir (BOC) is a direct-acting antiviral agent (DAA), which inhibits the NS3/4A serine protease required for RNA replication and virion assembly.2 BOC has demonstrated potent inhibition of HCV-1 replication and has resulted in markedly improved SVR rates of over 60% in treatment-naive and treatment-experienced HCV-1 patients in the past two years. Combining BOC with pegIFN and RBV limits the selection of resistant variants and improves antiviral response. BOC ha